Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Back to dashboard
Company Information
About this company
Key people
Lawrence Erik Kurzius
Independent Chairman of the Board
Rajeev Modi
Executive Vice President - U.S. Pet Health and Global Digital Transformation
Jose Manuel Correia de Simas
Executive Vice President - U.S. Farm Animal Business
Kapila Kapur Anand
Independent Director
Art A. Garcia
Independent Director
Michael J. Harrington
Independent Director
Paul S. Herendeen
Independent Director
Jeffrey N. Simmons
President, Chief Executive Officer, Director
Robert VanHimbergen
Executive Vice President, Chief Financial Officer
Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Timothy J. Bettington
Executive Vice President - Center of Strategic Growth
Ramiro M. Cabral
Executive Vice President; President of Elanco International
Ellen de Brabander
Executive Vice President - Innovation and Regulatory Affairs
Grace Mcardle
Executive Vice President - Manufacturing and Quality
Click to see more
Key facts
- Shares in issue499.62m
- EPICELAN
- ISINUS28414H1032
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$11.77bn
- Employees9,400
- ExchangeNew York Stock Exchange
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.